Spruce Street Capital LP Purchases Shares of 5,352,198 InflaRx N.V. $IFRX

Spruce Street Capital LP acquired a new stake in shares of InflaRx N.V. (NASDAQ:IFRX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 5,352,198 shares of the company’s stock, valued at approximately $11,988,924,000. InflaRx comprises about 2.4% of Spruce Street Capital LP’s investment portfolio, making the stock its 13th largest position.

A number of other institutional investors have also recently made changes to their positions in the company. Sanctuary Advisors LLC bought a new stake in shares of InflaRx in the second quarter worth about $25,000. DCF Advisers LLC bought a new position in InflaRx during the second quarter valued at approximately $512,000. ADAR1 Capital Management LLC bought a new position in InflaRx during the first quarter valued at approximately $142,000. XTX Topco Ltd purchased a new position in InflaRx during the 4th quarter valued at approximately $135,000. Finally, Suvretta Capital Management LLC grew its holdings in InflaRx by 22.4% during the 4th quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock valued at $8,013,000 after buying an additional 1,450,000 shares in the last quarter. Hedge funds and other institutional investors own 42.39% of the company’s stock.

InflaRx Price Performance

Shares of IFRX stock opened at $2.05 on Tuesday. The company has a market cap of $302.11 million, a PE ratio of -3.53 and a beta of 2.48. InflaRx N.V. has a 1 year low of $0.80 and a 1 year high of $2.95. The stock’s 50 day simple moving average is $1.94 and its two-hundred day simple moving average is $1.62.

InflaRx (NASDAQ:IFRX) last announced its earnings results on Friday, August 7th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.04). Equities research analysts expect that InflaRx N.V. will post -0.31 EPS for the current year.

Wall Street Analysts Forecast Growth

IFRX has been the topic of several recent research reports. Wall Street Zen raised InflaRx from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. HC Wainwright boosted their price target on shares of InflaRx from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Raymond James Financial raised shares of InflaRx from an “outperform” rating to a “strong-buy” rating and upped their price target for the company from $7.00 to $9.00 in a research note on Wednesday, May 13th. Cantor Fitzgerald increased their price objective on shares of InflaRx from $4.00 to $6.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of InflaRx in a research note on Wednesday, June 24th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.33.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.